VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patient diagnosed by HRCT Core Lab with eligible   │ Patient diagnosed by HRCT Core Lab with eligible   │     100 │
│ heterogeneous disease distribution and at least    │ heterogeneous disease distribution and at least    │         │
│ one complete oblique fissure                       │ one complete oblique fissure                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age from 40 to 75 years                            │ Age from 40 to 75 years                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Nonsmoking for 4 months prior to initial interview │ Nonsmoking for 4 months prior to initial interview │     100 │
│ and throughout screening                           │ and throughout screening                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patient agrees to all protocol required        │ The patient agrees to all protocol required        │     100 │
│ follow-up intervals                                │ follow-up intervals                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patient has no child bearing potential         │ The patient has no child bearing potential         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The patient is willing and able to complete        │ The patient is willing and able to complete        │     100 │
│ protocol required baseline assessments and         │ protocol required baseline assessments and         │         │
│ procedures                                         │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior endobronchial treatment for emphysema        │ Prior endobronchial treatment for emphysema        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pleural or interstitial disease that precludes     │ Pleural or interstitial disease that precludes     │     100 │
│ surgery                                            │ surgery                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior lung transplant, LVRS, median sternotomy,    │ Prior lung transplant, LVRS, median sternotomy,    │     100 │
│ bullectomy or lobectomy                            │ bullectomy or lobectomy                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically significant bronchiectasis              │ Clinically significant bronchiectasis              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pulmonary nodule requiring surgery                 │ Pulmonary nodule requiring surgery                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Fever, elevated white cell count, or other         │ Fever, elevated white cell count, or other         │     100 │
│ evidence of active infection                       │ evidence of active infection                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Dysrhythmia that might pose a risk during exercise │ Dysrhythmia that might pose a risk during exercise │     100 │
│ or training                                        │ or training                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence or history of Cor Pulmonale               │ Evidence or history of Cor Pulmonale               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Resting bradycardia (\< 50 beats/min), frequent    │ Resting bradycardia (< 50 beats/min), frequent     │     100 │
│ multifocal PVCs, complex ventricular arrhythmia,   │ multifocal PVCs, complex ventricular arrhythmia,   │         │
│ sustained SVT                                      │ sustained SVT                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of exercise-related syncope                │ History of exercise-related syncope                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of systemic disease or neoplasia expected │ Evidence of systemic disease or neoplasia expected │     100 │
│ to compromise survival during 5-yr period          │ to compromise survival during 5-yr period          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any disease or condition that interferes with      │ Any disease or condition that interferes with      │     100 │
│ completion of initial or follow-up assessments     │ completion of initial or follow-up assessments     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is currently enrolled in another clinical  │ Patient is currently enrolled in another clinical  │     100 │
│ trial                                              │ trial                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is unable to complete 3 minutes of         │ Patient is unable to complete 3 minutes of         │     100 │
│ unloaded peddling on cycle ergometer               │ unloaded peddling on cycle ergometer               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Alpha-1-Antitrypsin Deficiency                     │ Alpha-1-Antitrypsin Deficiency                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ BMI \< 32 kg/m2                                    │ BMI < 32 kg/m2                                     │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ PaCO2 \< 50mm Hg                                   │ PaCO2 < 50mm Hg                                    │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ FEV1 \< 40% of predicted value, FEV1/FVC \< 70%    │ FEV1 < 40% of predicted value, FEV1/FVC < 70%      │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ TLC \> 120% predicted, RV \> 150% predicted        │ TLC > 120% predicted, RV > 150% predicted          │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ PaO2 \> 45 mm Hg on room air                       │ PaO2 > 45 mm Hg on room air                        │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ MI within 6 mo and LVEF \< 45%                     │ MI within 6 mo and LVEF < 45%                      │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Stable with \< 20 mg prednisone (or equivalent) qd │ Stable with < 20 mg prednisone (or equivalent) qd  │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ 6-min walk of \> 50m (without rehabilitation) or   │ 6-min walk of > 50m (without rehabilitation) or >  │      99 │
│ \> 100m (with rehabilitation)                      │ 100m (with rehabilitation)                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of recurrent respiratory infections (\> 3  │ History of recurrent respiratory infections (> 3   │      99 │
│ hospitalization in the last year)                  │ hospitalization in the last year)                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically significant (\> 4 Tablespoons per day)  │ Clinically significant (> 4 Tablespoons per day)   │      99 │
│ sputum production                                  │ sputum production                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Congestive heart failure within 6 mo and LVEF \<   │ Congestive heart failure within 6 mo and LVEF <    │      99 │
│ 45%                                                │ 45%                                                │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria           │   Score │
╞═══════════════════════════════════╪═════════════════════════╪═════════╡
│ Must have minimum age of 40 Years │ Age from 40 to 75 years │      43 │
├───────────────────────────────────┼─────────────────────────┼─────────┤
│ Must have maximum age of 75 Years │ Age from 40 to 75 years │      50 │
╘═══════════════════════════════════╧═════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 96.29411764705883
OverAll Ratio: 97.14705882352942
